Drugs & Aging

, Volume 23, Issue 8, pp 673–680 | Cite as

Intravenous Esmolol is Well Tolerated in Elderly Patients with Heart Failure in the Early Phase of Non-ST Elevation Myocardial Infarction

  • Michael Koutouzis
  • Savvas Nikolidakis
  • Anestis Grigoriadis
  • Dimitrios Koutsogeorgis
  • Zenon S. Kyriakides
Original Research Article

Abstract

Aim

To investigate the haemodynamic response to and clinical safety and tolerability of intravenous esmolol (Brevibloc®, Baxter Healthcare Corporation, Deerfield, Illinois, USA) in elderly and younger patients with acute non-ST elevation myocardial infarction (NSTEMI) and heart failure.

Patients and methods

We studied 24 consecutive patients, 12 of them elderly (≥75 years old) and 12 younger (32–74 years old), with NSTEMI and symptoms of heart failure on presentation. After stabilisation of the patient’s condition with standard therapy, intravenous esmolol was administered. An infusion rate of 0.05 mg/kg/min for 30 minutes was instituted and, if no adverse effects developed, this was increased to 0.20 mg/kg/min. All haemodynamic parameters were measured before and at the end of each administration using a Swan-Ganz catheter.

Results

Only one patient in the elderly subgroup did not tolerate the augmented infusion rate (because of severe bradycardia) and so had to return to the initial lower infusion rate. The cardiac index (mean ± SD) was 2.4 ± 0.9 L/min/m2 at baseline and decreased to 1.9 ± 0.4 L/min/m2 (p < 0.05 vs baseline) at the end of the administration of the second dose of esmolol in the elderly patients and 2.6 ± 0.5 L/min/m2 and 2.2 ± 0.5 L/min/m2 (p < 0.05 vs baseline), respectively, in the younger patients. Mean pulmonary wedge pressure was 17 ± 6mm Hg at baseline and increased to 19 ± 4mm Hg (p < 0.05 vs baseline) at the end of the second dose of esmolol in the elderly patients and 16 ± 10mm Hg and 18 ± 10mm Hg (p < 0.05 vs baseline), respectively, in the younger patients. The response of both age groups to esmolol was the same for all of the parameters examined.

Conclusion

Intravenous esmolol was safe and well tolerated in the early phase of NSTEMI in patients presenting with symptoms of heart failure and ongoing ischaemia, regardless of their age.

Keywords

Acute Myocardial Infarction Esmolol Decompensated Heart Failure Muscle Sympathetic Nerve Activity Pulmonary Wedge Pressure 

Notes

Acknowledgements

No sources of funding were used to assist in the preparation of this article. The authors have no conflicts of interest that are directly relevant to the content of this study.

References

  1. 1.
    Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology/American Heart Association Committee on the Management of Patients with Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-elevation myocardial infarction. Summary article: a report of the ACC/AHA task force on practice guidelines (Committee on the Management of Patients with Unstable Angina). J Am Coll Cardiol 2002 Oct 2; 40: 1366–74PubMedCrossRefGoogle Scholar
  2. 2.
    Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985; 27: 335–71PubMedCrossRefGoogle Scholar
  3. 3.
    Herlitz J, Elmfeldt D, Hjalmarson A, et al. Effect of metoprolol on indirect signs of the size and severity of acute myocardial infarction. Am J Cardiol 1983; 51: 1282–8PubMedCrossRefGoogle Scholar
  4. 4.
    Nieminen MS, Bohm M, Cowie MR, et al. ESC Committee for Practice Guideline. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J 2005; 26: 384–416PubMedCrossRefGoogle Scholar
  5. 5.
    Kyriakides ZS, Papaioannou G, Paraskevaidis IA, et al. Systolic functional response of normal older and younger adult left ventricles to β-blockade during exercise. Cardiovasc Drugs Ther 1995 Apr; 9(2): 289–94PubMedCrossRefGoogle Scholar
  6. 6.
    Yin FC, Raizes GS, Guarnieri T, et al. Age-associated decrease in ventricular response to haemodynamic stress during beta-adrenergic blockade. Br Heart J 1978; 40: 1349–55PubMedCrossRefGoogle Scholar
  7. 7.
    Ahmed A. Myocardial beta-1 adrenoceptor down-regulation in aging and heart failure: implications for beta-blocker use in older adults with heart failure. Eur J Heart Fail 2003; 5(6): 709–15PubMedCrossRefGoogle Scholar
  8. 8.
    White M, Leenen FH. Effects of age on cardiovascular responses to adrenaline in man. Br J Clin Pharmacol 1997; 43(4): 407–14PubMedCrossRefGoogle Scholar
  9. 9.
    White M, Roden R, Minobe W, et al. Age-related changes in beta-adrenergic neuroeffector systems in the human heart. Circulation 1994; 90(3): 1225–38PubMedCrossRefGoogle Scholar
  10. 10.
    Feldman RD. Physiological and molecular correlates of age-related changes in the human beta-adrenergic receptor system. Fed Proc 1986; 45(1): 48–50PubMedGoogle Scholar
  11. 11.
    Lehmann M, Schmid P, Keul J. Age- and exercise-related sympathetic activity in untrained volunteers, trained athletes and patients with impaired left-ventricular contractility. Eur Heart J 1984; 5Suppl. E: 1–7PubMedCrossRefGoogle Scholar
  12. 12.
    GISSI-3. Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction: Gruppo Italiano per lo Studio della Sopravvivenza nell’infarto miocardico. Lancet 1994; 343: 1115–22Google Scholar
  13. 13.
    Barbier GH, Shettigar UR, Appunn DO. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol. Int J Clin Pharmacol Ther 1995; 33: 212–8PubMedGoogle Scholar
  14. 14.
    Grossman W. Blood flow measurement: the cardiac output. In: Grossman W, Baim DS, editors. Cardiac catheterization, angiography and intervention. 4th ed. Philadelphia (PA): Lea & Febiger, 1991: 105–22Google Scholar
  15. 15.
    Kyriakides ZS, Kremastinos D, Karavolias G, et al. Intravenous atenolol in elderly patients in the early phase of acute myocardial infarction. Cardiovasc Drugs Ther 1992; 6: 475–9PubMedCrossRefGoogle Scholar
  16. 16.
    Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986; 2(8498): 57–66Google Scholar
  17. 17.
    Metoprolol in acute myocardial infarction: patient population. The MIAMI Trial Research Group. Am J Cardiol 1985; 56(14): 10G–14GGoogle Scholar
  18. 18.
    Hunt SA, Baker DW, Chin MH, et al. ACC/AHA guidelines for the evaluation and management of chronic heart failure in the adult: executive summary a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure). Circulation 2001; 104: 2996–3007PubMedCrossRefGoogle Scholar
  19. 19.
    Gheorghiade M, Colucci WS, Swedberg K. β-blockers in chronic heart failure. Circulation 2003; 107: 1570–5PubMedCrossRefGoogle Scholar
  20. 20.
    Olivetti G, Melissari Capasso JM, Anversa P. Cardiomyopathy of the aging human heart: myocyte loss and reactive cellular hypertrophy. Circ Res 1991; 68: 1560–8PubMedCrossRefGoogle Scholar
  21. 21.
    White M, Leenen FHJ. Aging and cardiovascular responsiveness to β-agonist in humans: role of changes in β-receptor responses versus baroreflex activity. Clin Pharmacol Ther 1994; 56(5): 543–53PubMedCrossRefGoogle Scholar
  22. 22.
    Xiao RP, Lakatta EG. Deterioration of β-adrenergic modulation of cardiovascular function with aging. Ann N Y Acad Sci 1992; 673: 293–310PubMedCrossRefGoogle Scholar
  23. 23.
    Dillon N, Chung S, Kelly J, et al. Age and beta adrenoreceptor mediated function. Clin Pharmacol Ther 1980; 27: 769–72PubMedCrossRefGoogle Scholar
  24. 24.
    Kyriakides ZS, Kelesides K, Melanidis J, et al. Systolic functional response of normal older and younger adult left ventricles to dobutamine. Am J Cardiol 1986; 58: 816–9PubMedCrossRefGoogle Scholar
  25. 25.
    Rich MW, Imburgia M. Inotropic response to dobutamine in elderly patients with decompensated congestive heart failure. Am J Cardiol 1990; 65: 519–21PubMedCrossRefGoogle Scholar
  26. 26.
    Podrazik PM, Schwartz JB. Cardiovascular pharmacology of aging. Cardiol Clin 1999; 17(1): 17–34PubMedCrossRefGoogle Scholar
  27. 27.
    Proper R. Left ventricular stroke volume measurements not affected by chronologic aging. Am Heart J 1972; 83: 843–5PubMedCrossRefGoogle Scholar
  28. 28.
    COMMIT Collaborative Group. Early intravenous then oral metoprolol in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1622–32CrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Michael Koutouzis
    • 1
  • Savvas Nikolidakis
    • 1
  • Anestis Grigoriadis
    • 1
  • Dimitrios Koutsogeorgis
    • 1
  • Zenon S. Kyriakides
    • 1
  1. 1.B Cardiology DepartmentRed Cross General HospitalAthensGreece

Personalised recommendations